Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | ADA | P00813 | 1/20 | 0.50 |
| ▸ | AHCY | P23526 | 6/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9548828 | 1.00 | SLC28A1 (0.53) | SLC28A1SLC28A2ADAAHCYADORA3 | |
| SCHEMBL2525367 | 0.89 | SLC28A1 (0.53) | SLC28A1SLC28A2ADAAHCYADORA3 | |
| SCHEMBL2525364 | 0.89 | SLC28A1 (0.53) | SLC28A1SLC28A2ADAAHCYADORA3 | |
| SCHEMBL29654853 | 0.89 | SLC28A1 (0.53) | SLC28A1SLC28A2ADAAHCYADORA3 | |
| SCHEMBL31652753 | 0.89 | SLC28A1 (0.53) | SLC28A1SLC28A2ADAAHCYADORA3 | |
| SCHEMBL18670634 | 0.89 | SLC28A1 (0.53) | SLC28A1SLC28A2ADAAHCYADORA3 | |
| SCHEMBL9548676 | 0.87 | AHCY (0.50) | SLC28A1SLC28A2AHCYADORA3ADORA2A | |
| SCHEMBL9548688 | 0.87 | AHCY (0.50) | SLC28A1SLC28A2AHCYADORA3ADORA2A | |
| SCHEMBL12237558 | 0.87 | AHCY (0.50) | SLC28A1SLC28A2AHCYADORA3ADORA2A | |
| SCHEMBL2523180 | 0.85 | AHCY (0.52) | SLC28A1SLC28A2AHCYADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | SLC28A1 87/4885SLC28A2 100/4885ADA 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.